Hey 140IDs. Express Scripts is just one Pharmacy Benefit Manager, and they handle hundreds of different drugs. One drug denied does not make it an industry wide wholesale change even among the PBMs.. Talk about trying to distort the truth. You sound like Terry. Oh wait, you are Terry!!!
Bugsey. The best will be to see how hard he works when there is really good news. I can't forget the time when he probably had over 500 entries that day!!
Terry, I'm sure you have heard the saying "Figures don't lie, but liars do figure" It's great you're up a gazillion percent in your imaginary investment in Insmed based upon January 1, 2014 to now. But there are many longs that did not purchase on January 1, 2014.
If they bought on July 1, 2013 at $9.72, they are up about 70%
If they bought on Dec 31, 2012 at $6.69%, they are up about 146%
If they bought on Dec 19, 2013 at $15.29, they are up about 7.8%
Most of the longs are here because of the prospects of good results in the future. Go ahead and trade your 50 shares all day, because we don't care. So if it makes you feel good to lie, deceive , distort, and manipulate the facts, we can't help you and your sorry #$%$ lying loser characteristics, but we can counteract your falsehoods with facts.
Would you care to speculate what the need for up to $90 million of funds could be used for in the future?
Would drug manufacturing and marketing use a lot of those funds, or could they use it to fund additional trials? That's on top of the 170? million they have in funds today.
Oh Terry. It's too bad you have to try and deceive people with all your cloned IDs. The only people who believe you are all your alter ego IDs. Too bad we don't have a picture of you, as we could give it to a Picture Dictionary and have it posted next to the definition of LOSER!!
Rook. Terry and the IDs can't supply facts, because it's not in their DNA. Terry will have to take his orders from someone else, as he is the Novartis shill on this board. Go ahead and mention IPLEX and its benefits and how they might effect Insmed in the future, we can sit back and watch the MB fireworks begin!!
Bo. Was that your synopsis of what it might be, or did you obtain that information from another source?
The article didn't state any particular collaboration with another company. I'm assuming the collaboration is the Cystic Fibrosis Foundation as they will be using some of the money they obtained when the deal with Vertex was transacted a few months back.
From Fierce Biotech today:
Shire, settling into life on its own after a failed merger with AbbVie ($ABBV), believes its in-development drugs can bring in a combined $3 billion in sales by 2020, sharpening its focus on rare diseases and keeping an eye out for bolt-on acquisitions.
At its R&D day in New York, Shire ($SHPG) pulled back the veil on its pipeline, pointing to a company-record 22 candidates in clinical development and heralding a new collaboration that will broaden its work in cystic fibrosis.
Among Shire's most promising assets is SHP607, a protein-replacement therapy for the rare retinopathy of prematurity, which affects premature infants. The treatment, currently in Phase II, received the FDA's fast-track designation, Shire said, guaranteeing a speedy regulatory review if and when it completes pivotal trials.
Short is telling BOD the higher the rainfall number, the larger increase in bonus he should receive. Because that will mean better rice harvest, and more rice bran to have available for rice bran oil, or whatever he is selling the BOD on. Obviously, the BOD cannot think or evaluate performance on its own. Short probably can't believe how lucky he is with this BOD. Selling sunglasses or underwear is usually tied to number of product sold, or (you might find this hard to believe) to profitability.
Merck Buys Cubist For $8.4 Billion.
Cubist will have around $1 billion in revenue next year so the price is 8.4x next year's sales. If we generate 20,000 total NTM patients in 2016 - about half of the EU afflicted - we're looking at the same $1 billion in revenue. Add to that CF patients and it is much more. And, soon after, the US market and the rest of the world comes online. Finally, Iplex is back by 2018. We may see over $160 per share in a year - or more.
I guess Premacure is now Shire? Do you think Shire would have the capacity to make Iplex in larger batches or quantities once they start?